MNKD · Insider Trading
Mannkind Corporation
Every open-market purchase and sale reported by MNKD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-28 | Steven B. Binder | Director | Sell | −39,051 | −$128.48K |
| 2026-09-14 | Steven B. Binder | Director | Sell | −33,558 | −$127.86K |
| 2026-08-10 | Steven B. Binder | Director | Sell | −39,051 | −$158.55K |
| 2026-07-17 | Dominic Marasco | Pres, Endocrine Business Unit | F | −3,623 | −$14.82K |
| 2026-07-17 | Sanjay R Singh | EVP Technical Operations | MIXED | +23,755 | −$191.39K |
| 2026-07-17 | Michael Castagna | Chief Executive Officer | MIXED | −12,940 | −$1.49M |
| 2026-07-17 | Christopher B Prentiss | Chief Financial Officer | F | −22,247 | −$90.99K |
| 2026-07-17 | Stuart A Tross | Chief People & Workpl Officer | MIXED | +27,982 | −$269.15K |
| 2026-07-17 | Steven B. Binder | Director | MIXED | +16,910 | −$312.86K |
| 2026-07-17 | David Thomson | EVP Genl Counsel & Secretary | MIXED | −28,745 | −$500.20K |
| 2026-05-22 | Stuart A Tross | Chief People & Workpl Officer | A | +33,898 | +$100.00K |
| 2026-05-22 | Anthony C Hooper | Director | A | +99,337 deriv. | — |
| 2026-05-22 | Michael A Friedman | Director | A | +82,781 deriv. | — |
| 2026-05-22 | Jennifer Grancio | Director | A | — | — |
| 2026-05-22 | Sabrina Kay | Director | A | — | — |
| 2026-05-22 | Steven B. Binder | Director | A | +82,781 deriv. | — |
| 2026-05-22 | Ronald J Consiglio | Director | A | +10,000 | +$29.50K |
| 2026-05-22 | James Samuel Shannon | Director | A | — | — |
| 2026-05-22 | Christine Mundkur | Director | A | — | — |
| 2026-05-22 | Dominic Marasco | Pres, Endocrine Business Unit | A | +8,474 | +$25.00K |
| 2026-05-13 | David Thomson | EVP Genl Counsel & Secretary | MIXED | −15,420 | −$53.58K |
| 2026-05-13 | Stuart A Tross | Chief People & Workpl Officer | F | −8,073 | −$28.42K |
| 2026-05-13 | Steven B. Binder | Director | MIXED | −22,500 | −$75.30K |
| 2026-05-13 | Michael Castagna | Chief Executive Officer | F | −34,957 | −$123.05K |
| 2026-05-08 | Michael Castagna | Chief Executive Officer | — | — | — |
| 2026-04-24 | Christopher B Prentiss | Chief Financial Officer | F | −12,267 | −$33.61K |
| 2026-03-25 | Michael Castagna | Chief Executive Officer | A | +1,578,000 deriv. | — |
| 2026-03-25 | Christopher B Prentiss | Chief Financial Officer | A | +438,000 deriv. | — |
| 2026-03-25 | Ajay Ahuja | Chief Medical Officer | A | +438,000 deriv. | — |
| 2026-03-25 | David Thomson | EVP Genl Counsel & Secretary | A | +438,000 deriv. | — |
| 2026-03-25 | Sanjay R Singh | EVP Technical Operations | A | +438,000 deriv. | — |
| 2026-03-25 | Stuart A Tross | Chief People & Workpl Officer | A | +438,000 deriv. | — |
| 2026-03-10 | Michael Castagna | Chief Executive Officer | Buy | +100,000 | +$259.00K |
| 2026-03-03 | Anthony C Hooper | Director | A | +35,000 | +$114.45K |
| 2026-03-03 | James Samuel Shannon | Director | A | +12,000 | +$39.24K |
| 2026-03-03 | Christopher B Prentiss | Chief Financial Officer | A | +5,000 | +$16.35K |
| 2026-03-02 | Michael Castagna | Chief Executive Officer | A | +15,290 | +$50.00K |
| 2026-03-02 | David Thomson | EVP Genl Counsel & Secretary | A | +57,525 deriv. | — |
| 2026-03-02 | Steven B. Binder | Director | A | +45,025 deriv. | — |
| 2026-03-02 | Stuart A Tross | Chief People & Workpl Officer | A | +15,290 | +$50.00K |
| 2026-01-09 | Stuart A Tross | Chief People & Workpl Officer | Sell | −47,006 | −$297.55K |
| 2025-12-29 | Michael Castagna | Chief Executive Officer | G | −44,171 | — |
| 2025-12-19 | Michael Castagna | Chief Executive Officer | MIXED | — | −$96.07K |
| 2025-12-16 | Michael Castagna | Chief Executive Officer | MIXED | — | −$61.07K |
| 2025-12-04 | Michael Castagna | Chief Executive Officer | MIXED | — | −$110.08K |
| 2025-12-04 | David Thomson | EVP Genl Counsel & Secretary | MIXED | — | −$146.35K |
| 2025-11-14 | Sanjay R Singh | EVP Technical Operations | Sell | −18,777 | −$94.45K |
| 2025-11-12 | Ajay Ahuja | Chief Medical Officer | A | +318,200 | — |
| 2025-11-03 | Sanjay R Singh | EVP Technical Operations | F | −17,071 | −$95.43K |
| 2025-09-17 | Stuart A Tross | Chief People & Workpl Officer | Sell | −47,000 | −$250.98K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Michael Castagna | Chief Executive Officer | 2,605,660 | $8.17M |
| Stuart A Tross | Chief People & Workpl Officer | 1,058,142 | $3.32M |
| David Thomson | EVP Genl Counsel & Secretary | 868,457 | $2.72M |
| Steven B. Binder | Director | 713,258 | $2.24M |
| Sanjay R Singh | EVP Technical Operations | 478,966 | $1.50M |
| Burkhard Blank | EVP Chief Medical Officer | 460,791 | $1.44M |
| Lauren M Sabella | EVP Operations | 349,841 | $1.10M |
| Dominic Marasco | Pres, Endocrine Business Unit | 343,398 | $1.08M |
| Christopher B Prentiss | Chief Financial Officer | 318,668 | $999.02K |
| Ajay Ahuja | Chief Medical Officer | 318,200 | $997.56K |
| Anthony C Hooper | Director | 236,153 | $740.34K |
| Ronald J Consiglio | Director | 132,342 | $414.89K |
| Jennifer Grancio | Director | 110,701 | $347.05K |
| Sabrina Kay | Director | 107,033 | $335.55K |
| James Samuel Shannon | Director | 36,458 | $114.30K |
| Christine Mundkur | Director | 27,675 | $86.76K |
| Michael A Friedman | Director | 9,500 | $29.78K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MNKD quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.